Drugs / Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Bivalent BNT162b2 (original/Omicron BA.4/BA.5)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05543616 | Sep 2022 → Jul 2026 overdue | COVID-19 | BioNTech SE | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bivalent BNT162b2 (original/Omicron BA.4/BA.5) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05543616 ↗ |
| Modality | Messenger RNA (mRNA) | “variant-adapted BNT162b2 RNA-based vaccine” NCT05543616 ↗ |
| Route | Intramuscular | “Injection in the muscle” NCT05543616 ↗ |